Key result
An anthracycline infusion duration of six hours or longer significantly reduced the risk of clinical heart failure compared to a shorter infusion duration (RR 0.27).
Why the study?
Do longer anthracycline infusion durations or different peak doses reduce the occurrence of clinical heart failure in people with cancer?
Systematic Review (n=6,083)
Do longer anthracycline infusion durations or different peak doses reduce the occurrence of clinical heart failure in people with cancer?
Relative Risk: 0.27 (95% CI 0.09–0.81)
Administering anthracyclines via continuous infusion for 6 hours or longer significantly reduces the risk of clinical heart failure compared to shorter infusions in adults with solid tumors.
No takes yet. Share an insight, caveat, or question.
Prolonged anthracycline infusions warrant consideration to reduce clinical heart failure; confirms benefit in adults with solid tumors.
Dalen et al. (2016) conducted a systematic review in Cancer (n=6,083). Anthracycline infusion duration ≥ 6 hours vs. Anthracycline infusion duration < 6 hours was evaluated on Clinical heart failure (RR 0.27, 95% CI 0.09-0.81). An anthracycline infusion duration of six hours or longer significantly reduced the risk of clinical heart failure compared to a shorter infusion duration (RR 0.27).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: